Published guidelines and consensus statements have identified serum Lp(a) over 30 mg/dL as hyperlipoproteinemia(a) and recommended screening to lower the Lp(a)-mediated risk of cardiovascular events [10]. The gene discussed is LPA; the disease is hyperlipoproteinemia.